SMAD3 and renal fibrosis: HIPK2, a regulator of the TGF-β1/Smad3 pathway, inhibited Smad3 phosphorylation, leading to the mitigation of renal fibrosis (Liu et al., 2017), which indicated that Smad3 is a potential therapeutic target for T2DN.